Zhang L - Search Results

1

Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy.

Fang W, Huang Y, Gan J, Zheng Q, Zhang L. Fang W, et al. Among authors: zhang l. J Thorac Oncol. 2020 Mar;15(3):e36-e37. doi: 10.1016/j.jtho.2019.09.198. J Thorac Oncol. 2020. PMID: 32093857 Free article. No abstract available.

2

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.

Ma Y, Zheng X, Zhao H, Fang W, Zhang Y, Ge J, Wang L, Wang W, Jiang J, Chuai S, Zhang Z, Xu W, Xu X, Hu P, Zhang L. Ma Y, et al. Among authors: zhang l, zhang z, zhang y. J Thorac Oncol. 2018 Jul;13(7):968-977. doi: 10.1016/j.jtho.2018.03.025. Epub 2018 Apr 4. J Thorac Oncol. 2018. PMID: 29626621 Free article. Clinical Trial.

3

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.

Fang W, Huang Y, Hong S, Zhang Z, Wang M, Gan J, Wang W, Guo H, Wang K, Zhang L. Fang W, et al. Among authors: zhang l, zhang z. BMC Cancer. 2019 Jun 17;19(1):595. doi: 10.1186/s12885-019-5820-0. BMC Cancer. 2019. PMID: 31208370 Free PMC article.

4

MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.

Fang W, Gan J, Hong S, Lu F, Zhang L. Fang W, et al. Among authors: zhang l. J Thorac Oncol. 2019 Jul;14(7):e148-e151. doi: 10.1016/j.jtho.2019.02.030. J Thorac Oncol. 2019. PMID: 31235041 Free article. No abstract available.

5

A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.

Fang W, Huang Y, Gan J, Hong S, Zhang L. Fang W, et al. Among authors: zhang l. J Thorac Oncol. 2019 Sep;14(9):e201-e202. doi: 10.1016/j.jtho.2019.04.013. J Thorac Oncol. 2019. PMID: 31445736 Free article. No abstract available.

6

Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.

Fang W, Huang Y, Gan J, Shao YW, Zhang L. Fang W, et al. Among authors: zhang l. J Thorac Oncol. 2019 Oct;14(10):e220-e221. doi: 10.1016/j.jtho.2019.05.023. J Thorac Oncol. 2019. PMID: 31558231 Free article. No abstract available.

7

Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.

Fang W, Gan J, Huang Y, Zhou H, Zhang L. Fang W, et al. Among authors: zhang l. J Thorac Oncol. 2019 Dec;14(12):e274-e275. doi: 10.1016/j.jtho.2019.07.018. J Thorac Oncol. 2019. PMID: 31757379 Free article. No abstract available.

8

Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.

Zhao S, Fang W, Pan H, Yang Y, Liang Y, Yang L, Dong X, Zhan J, Wang K, Zhang L. Zhao S, et al. Among authors: zhang l. J Thorac Oncol. 2020 Jun;15(6):962-972. doi: 10.1016/j.jtho.2020.01.020. Epub 2020 Feb 7. J Thorac Oncol. 2020. PMID: 32036069 Free article.

9

Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia.

Fang W, Huang Y, Gan J, He B, Zhang L. Fang W, et al. Among authors: zhang l. J Thorac Oncol. 2020 Mar;15(3):e34-e35. doi: 10.1016/j.jtho.2019.09.086. J Thorac Oncol. 2020. PMID: 32093856 Free article. No abstract available.

10

Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.

Zheng Q, Fang W, Huang Y, Gan J, Zhang L. Zheng Q, et al. Among authors: zhang l. J Thorac Oncol. 2020 Aug;15(8):e132-e133. doi: 10.1016/j.jtho.2019.12.114. J Thorac Oncol. 2020. PMID: 32718536 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135,399 results

Search Page

Filters